RGLS vs. XOMA, RIGL, VNDA, VSTM, SGMO, LXRX, ACHV, AGEN, FBIO, and SABS
Should you be buying Regulus Therapeutics stock or one of its competitors? The main competitors of Regulus Therapeutics include XOMA (XOMA), Rigel Pharmaceuticals (RIGL), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), Achieve Life Sciences (ACHV), Agenus (AGEN), Fortress Biotech (FBIO), and SAB Biotherapeutics (SABS). These companies are all part of the "biotechnology" industry.
Regulus Therapeutics vs.
Regulus Therapeutics (NASDAQ:RGLS) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, community ranking, valuation, analyst recommendations, media sentiment and institutional ownership.
Regulus Therapeutics has a net margin of 0.00% compared to XOMA's net margin of -151.34%. XOMA's return on equity of -24.95% beat Regulus Therapeutics' return on equity.
Regulus Therapeutics received 52 more outperform votes than XOMA when rated by MarketBeat users. However, 65.96% of users gave XOMA an outperform vote while only 63.80% of users gave Regulus Therapeutics an outperform vote.
In the previous week, Regulus Therapeutics had 6 more articles in the media than XOMA. MarketBeat recorded 10 mentions for Regulus Therapeutics and 4 mentions for XOMA. Regulus Therapeutics' average media sentiment score of 0.51 beat XOMA's score of 0.27 indicating that Regulus Therapeutics is being referred to more favorably in the media.
92.4% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, 95.9% of XOMA shares are owned by institutional investors. 4.4% of Regulus Therapeutics shares are owned by insiders. Comparatively, 7.2% of XOMA shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Regulus Therapeutics has higher earnings, but lower revenue than XOMA. XOMA is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Regulus Therapeutics presently has a consensus target price of $10.80, suggesting a potential upside of 770.97%. XOMA has a consensus target price of $81.50, suggesting a potential upside of 204.56%. Given Regulus Therapeutics' higher possible upside, analysts clearly believe Regulus Therapeutics is more favorable than XOMA.
Regulus Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, XOMA has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
Summary
Regulus Therapeutics beats XOMA on 10 of the 17 factors compared between the two stocks.
Get Regulus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regulus Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RGLS) was last updated on 1/20/2025 by MarketBeat.com Staff
Free RGLS Stock Alerts